PPD, Inc.

PPD, Inc.
TypeSubsidiary
IndustryContract research organizations
Pharmaceutical
Biotechnology
Founded1985
HeadquartersWaltham, Massachusetts, United States
Key people
See Senior Leadership Team page of the PPD Website[1]
ProductsContract clinical research for pharmaceutical, biotechnology, medical device, academic and government organizations; services include drug development, laboratory and lifecycle management.
RevenueIncrease $4.7 Billion (2020)[2]
Number of employees
27,000+ (2021)
ParentThermo Fisher Scientific
Websitehttps://www.ppd.com

Pharmaceutical Product Development (PPD) is a global contract research organization (CRO) providing comprehensive, integrated drug development, laboratory and lifecycle management services. In December 2021, PPD became a wholly owned subsidiary of Thermo Fisher Scientific.

History

PPD was founded by Fred Eshelman, Pharm.D., as a one-person consulting firm in 1985. The following year he expanded the company's scope to include development services and relocated operations from Maryland to North Carolina.

  • July 1985: Fred Eshelman, Pharm.D., founds PPD as a one-person consulting firm based in his home in Maryland.
  • 1986: Eshelman expands the company and relocates operations to Wilmington, North Carolina.
  • January 1989: The company incorporates in North Carolina.
  • January 1996: PPD issues its initial public stock offering and begins trading on the Nasdaq National Market System under the symbol PPDI.
  • October 2005: PPD's board of directors adopts an annual cash dividend policy.
  • July 2009: The company promotes Eshelman to executive chairman and names David Grange chief executive officer.[3]
  • January 2010: The company commemorates the 25th anniversary of its founding.
  • June 2010: PPD spins off its compound partnering division as a new and independent publicly traded company, Furiex Pharmaceuticals.[4]
  • May 2011: David Grange retires as chief executive officer of PPD.[5]
  • September 2011: PPD's board of directors names Raymond Hill as PPD's new chief executive officer.[6]
  • December 2011: The company is acquired by affiliates of The Carlyle Group and affiliates of Hellman & Friedman in an all-cash transaction valued at approximately $3.9 billion.[7]
  • May 2012: PPD's board of directors names David Simmons as chairman and CEO.[8]
  • August 2013: PPD acquires Acurian.[9]
  • December 2014: PPD announces an agreement with SNBL to form a joint venture to provide full range of clinical development services in Japan.[10]
  • May 2015: PPD expands network of U.S.-based research sites via strategic relationship with Radiant.
  • June 2016: PPD expands network of global research sites via strategic relationship with Synexus.
  • September 2016: PPD acquires Evidera.[11]
  • April 2017: Hellman & Friedman and affiliates of The Carlyle Group enter into definitive agreements to recapitalize PPD and expand the company's ownership to include two new investors, a subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC Private Limited, Singapore's sovereign wealth fund.[12]
  • July 2018: PPD launches new site solution.[13]
  • July 2018: Synexus announces U.S.-based registry to power major longitudinal study on brain aging.[14]
  • February 2019: PPD inks deal with China's HLT to create data science-driven research solutions.[15]
  • May 2019: PPD's Evidera acquires RWE provider Medimix.[16]
  • September 2019: PPD's Accelerated Enrollment Solutions acquires global site business from Bioclinica.[17]
  • February 2020: PPD issues its initial public stock offering and begins trading on the Nasdaq Global Select Market under the symbol PPD.[18]
  • April 2021: Thermo Fisher Scientific announces plans to acquire PPD.[19]
  • December 2021: Thermo Fisher Scientific completes the acquisition of PPD. [20]

Location

PPD had its headquarters in Wilmington, North Carolina. The company has more than 27,000 employees. As of December 2021, PPD became a wholly owned subsidiary of Thermo Fisher Scientific based in Waltham, Massachusetts.

References

  1. ↑ "Senior Leadership Team". Retrieved 11 May 2021.
  2. ↑ https://www.macrotrends.net/stocks/charts/PPD/ppd/revenue
  3. ↑ Wayne Faulkner (May 19, 2009). "David Grange named CEO of PPD; Eshelman named executive chairman". Wilmington StarNews.
  4. ↑ "PPD and Furiex Announce Completion of Spin-off". Retrieved 12 June 2018.
  5. ↑ Wayne Faulkner (May 20, 2011). "David Grange retires as CEO of PPD". Wilmington StarNews.
  6. ↑ "PPD appoints Raymond Hill as chief executive officer and member of the board of directors". 12 June 2018.
  7. ↑ Peter Lattman (October 3, 2011). "Buyout Firms to Buy Drug Research Company for $3.9 Billion". New York Times.
  8. ↑ William Faulkner (May 23, 2012). "PPD names new CEO". Wilmington StarNews.
  9. ↑ "PPD Acquires Acurian, Industry Leader in Patient Recruitment and Retention". August 27, 2013.
  10. ↑ John Murawski (December 24, 2014). "PPD enters into joint venture with Japanese company". The News & Observer.
  11. ↑ Ben Adams (September 8, 2016). "PPD ties off Evidera merger deal, establishes 'real world research' leader". FierceBiotech.
  12. ↑ PPD (April 26, 2017). "PPD to Recapitalize with Existing Owners and Investors".
  13. ↑ Melissa Fassbender (July 2, 2018). "PPD flips the patient enrollment model and launches new site solution".
  14. ↑ PPD (July 23, 2018). "Synexus Announces U.S.-Based Registry to Power Major Longitudinal Study on Brain Aging".
  15. ↑ Joseph Keenan (February 28, 2019). "PPD inks deal with China's HLT to create data science-driven research solutions". FierceBiotech.
  16. ↑ Melissa Fassbender (May 30, 2019). "PPD's Evidera acquires RWE provider Medimix". Outsourcing-Pharma.
  17. ↑ PPD (September 5, 2019). "PPD's Accelerated Enrollment Solutions Acquires Global Site Business from Bioclinica".
  18. ↑ Joshua Franklin (February 5, 2020). "Drug research firm PPD prices IPO at top end of target". Reuters.
  19. ↑ "Thermo Fisher buying PPD in deal worth $17.4 billion". AP News. 2021-04-15.
  20. ↑ "Thermo Fisher Scientific Completes Acquisition of PPD, Inc". PR newswire. 2021-12-08.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.